

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">ATTY. DOCKET NO.</td> <td style="width: 50%;">SERIAL NO.</td> </tr> <tr> <td>U 016154-7</td> <td>10/568628</td> </tr> <tr> <td colspan="2" style="text-align: center;">APPLICANT</td> </tr> <tr> <td colspan="2" style="text-align: center;">HIROHIKO HOHJOH</td> </tr> <tr> <td>FILING DATE</td> <td>GROUP</td> </tr> <tr> <td> </td> <td> </td> </tr> </table>		ATTY. DOCKET NO.	SERIAL NO.	U 016154-7	10/568628	APPLICANT		HIROHIKO HOHJOH		FILING DATE	GROUP		
ATTY. DOCKET NO.	SERIAL NO.														
U 016154-7	10/568628														
APPLICANT															
HIROHIKO HOHJOH															
FILING DATE	GROUP														

U.S. PATENT DOCUMENTS					
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)		
	AR	EFFECTS ON RNA INTERFERENCE IN GENE...NUCLEIC ACID DRUG DEV.: 2002. VOL. 12; PAGES 301 TO 309
/K.C./	AS	HOHJOH H, ET AL.; RNA INTERFERENCE...HUMAN CELLS; FEBS LETT.; 2002; VOL. 521; PAGES 195 TO 199
/K.C./	AT	HOHJOH H. ET AL.; ENHANCEMENT OF RNAi ACTIVITY BY IMPROVED siRNA DUPLEXES; FEBS LETTERS; 2004 JANUARY; VOL. 557, PAGES 193 TO 198

EXAMINER /Kimberly Chong/	DATE CONSIDERED 01/21/2008
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	